Stockscreener 앱 받기
1.03
5.50%
-0.06
전일 마감가:
$1.09
열려 있는:
$1.12
하루 거래량:
920.75K
Relative Volume:
0.69
시가총액:
$119.61M
수익:
-
순이익/손실:
$-21.32M
주가수익비율:
-4.588
EPS:
-0.2245
순현금흐름:
$-19.96M
1주 성능:
-8.04%
1개월 성능:
+11.53%
6개월 성능:
-14.17%
1년 성능:
+76.58%
1일 변동 폭
$1.00
$1.12
1주일 범위
$1.00
$1.185
52주 변동 폭
$0.3258
$1.51
Oncolytics Biotech Inc Stock (ONCY) Company Profile
명칭
Oncolytics Biotech Inc
전화
(403) 670-7377
주소
804, 322 - 11 AVENUE SW, CALGARY, AB
Compare ONCY vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONCY
Oncolytics Biotech Inc
|
1.03 | 119.61M | 0 | -21.32M | -19.96M | -0.2245 |
VRTX
Vertex Pharmaceuticals Inc
|
430.29 | 109.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
751.57 | 79.46B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
780.25 | 48.52B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
305.54 | 40.77B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.80 | 33.39B | 5.36B | 287.73M | 924.18M | 2.5229 |
Oncolytics Biotech Inc Stock (ONCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-13 | 개시 | Lake Street | Buy |
| 2022-10-06 | 개시 | Maxim Group | Buy |
| 2021-02-17 | 개시 | H.C. Wainwright | Buy |
Oncolytics Biotech Inc 주식(ONCY)의 최신 뉴스
Oncolytics Could Re-Rate As Pelareorep Focuses On Registrational Paths (NASDAQ:ONCY) - Seeking Alpha
ONCY (Oncolytics Biotech Inc. Common Shares) posts wider Q3 2025 loss than consensus estimates, shares rise 5.66 percent.Social Investment Platform - Xã Thanh Hà
ONCY Stock Price, Quote & Chart | ONCOLYTICS BIOTECH INC (NASDAQ:ONCY) - ChartMill
ONCY Should I Buy - Intellectia AI
Q1 EPS Forecast for Oncolytics Biotech Lifted by Analyst - MarketBeat
Published on: 2026-04-14 02:49:57 - baoquankhu1.vn
Equities Analysts Issue Forecasts for ONCY Q1 Earnings - MarketBeat
Growth Report: What is Oncolytics Biotech Incs market position2026 Top Gainers & Verified Short-Term Plans - baoquankhu1.vn
Aug Outlook: Is Oncolytics Biotech Inc forming a breakout patternDividend Hike & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Published on: 2026-04-11 14:11:15 - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy - Investing.com UK
H.C. Wainwright reiterates Oncolytics Biotech stock rating at buy By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Is Oncolytics Biotech (ONCY) Price Reset Creating A Long Term Opportunity? - Sahm
Oncolytic Virotherapy Market size to reach $111.76 Billion - openPR.com
Q1 Earnings Estimate for ONCY Issued By Zacks Research - MarketBeat
What is Zacks Research's Forecast for ONCY FY2026 Earnings? - MarketBeat
Lake Street Maintains Oncolytics Biotech(ONCY.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
Oncolytics Biotech Inc. Announces $75 Million Open Market Sale Agreement with Jefferies LLC - Minichart
Oncolytics Biotech Inc. (ONCY) latest stock news and headlines - Yahoo Finance Singapore
Oncolytics schedules FDA meeting on anal cancer drug pathway By Investing.com - Investing.com Canada
Oncolytics Biotech Establishes $75 Million ATM Offering - TipRanks
Oncolytics Biotech (NASDAQ: ONCY) sets up $75M ATM facility - Stock Titan
Oncolytics Biotech (NASDAQ: ONCY) launches $75M ATM with Jefferies - Stock Titan
ONCY Technical Analysis & Stock Price Forecast - Intellectia AI
Oncolytics (ONCY) Targets FDA Meeting for Pelareorep's Anal Canc - GuruFocus
Oncolytics Biotech Inc - Baystreet.ca
Stocks in play: Oncolytics Biotech Inc - Barchart.com
Oncolytics (ONCY) Targets FDA Meeting for Pelareorep's Anal Cancer Pathway - GuruFocus
Oncolytics schedules FDA meeting on anal cancer drug pathway - Investing.com
Oncolytics Plans FDA Meeting for Pelareorep SCAC Study - tipranks.com
Oncolytics Biotech schedules Type C FDA meeting to discuss single-arm registrational study for pelareorep in anal cancer - TradingView
Oncolytics Biotech (NASDAQ: ONCY) targets single-arm pivotal SCAC path - Stock Titan
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer - The Manila Times
Oncolytics Biotech Inc announces a meeting focused on its single-arm pivotal study of candidate drug Pelareorep in second-line and later metastatic colorectal adenocarcinoma (SCAC) patients - bitget.com
Oncolytics Biotech® Announces Type C FDA Meeting To Discuss Single-Arm Registrational Pathway For Pelareorep In Anal Cancer - TradingView — Track All Markets
Oncolytics Biotech® Announces Type C FDA Meeting to Discuss - GlobeNewswire
Oncolytics Biotech Inc. (NASDAQ:ONCY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
[EFFECT] ONCOLYTICS BIOTECH INC SEC Filing - Stock Titan
Oncolytics Biotech Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer - Bitget
Oncolytics Biotech (NASDAQ:ONCY) Upgraded to Hold at Wall Street Zen - MarketBeat
Oncolytics Biotech Inc. (ONCY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Oncolytics Biotech: Revenue and Earnings Analysts Forecasts Revisions | ONYN | US68237V1035 - marketscreener.com
Oncolytics Biotech Inc.: Performance & Quotes, ONCY Stock Price on Nasdaq Exchange - marketscreener.com
Oncolytics Biotech: Financial Data Forecasts Estimates and Expectations | ONYN | US68237V1035 - marketscreener.com
Oncolytics Biotech: Target Price Consensus and Analysts Recommendations | ONYN | US68237V1035 - marketscreener.com
Oncolytics Biotech’s U.S. Move Resets Regulatory Path And Valuation Debate - Sahm
Oncolytics Biotech: Target Price Consensus and Analysts Recommendations | ONCY | US68237V1035 - marketscreener.com
Oncolytics Biotech Inc.: Financial Data Forecasts Estimates and Expectations | ONCY | US68237V1035 - marketscreener.com
Oncolytics Biotech: Revenue and Earnings Analysts Forecasts Revisions | ONCY | US68237V1035 - MarketScreener
Oncolytics Biotech Inc (ONCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.01%
0.61%
자본화:
|
볼륨(24시간):